(Q37634856)

21 August 2017

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide (English)

1 reference

21 August 2017

Henrik Østergaard

1

1 reference

21 August 2017

Jais R Bjelke

2

1 reference

21 August 2017

Lene Hansen

3

1 reference

21 August 2017

Lars Christian Petersen

4

1 reference

21 August 2017

Anette A Pedersen

5

1 reference

21 August 2017

Torben Elm

6

1 reference

21 August 2017

Flemming Møller

7

1 reference

21 August 2017

Mette B Hermit

8

1 reference

21 August 2017

Pernille K Holm

9

1 reference

21 August 2017

Thomas N Krogh

10

1 reference

21 August 2017

Jørn M Petersen

11

1 reference

21 August 2017

Mirella Ezban

12

1 reference

21 August 2017

Brit B Sørensen

13

1 reference

21 August 2017

Mette D Andersen

14

1 reference

21 August 2017

Henrik Agersø

15

1 reference

21 August 2017

Haleh Ahmadian

16

1 reference

21 August 2017

Kristoffer W Balling

17

1 reference

21 August 2017

Marie Louise S Christiansen

18

1 reference

21 August 2017

Karin Knobe

19

1 reference

21 August 2017

Timothy C Nichols

20

1 reference

21 August 2017

Søren E Bjørn

21

1 reference

21 August 2017

Mikael Tranholm

22

1 reference

21 August 2017

language of work or name

English

0 references

publication date

23 June 2011

1 reference

21 August 2017

1 reference

21 August 2017

118

1 reference

21 August 2017

8

1 reference

21 August 2017

2333-2341

1 reference

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Pharmacokinetic consequences of pegylation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

World Federation of Haemophilia programs in developing countries

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Effect of pegylation on pharmaceuticals

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Identification of the endothelial cell binding site for factor IX.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Isolation and characterization of a cDNA coding for human factor IX

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The molecular basis of blood coagulation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Biochemical characterization of recombinant factor IX.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The manufacturing process for recombinant factor IX.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The tissue factor region that interacts with substrates factor IX and Factor X.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Clinical evaluation of recombinant factor IX.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

A coagulation factor IX-deficient mouse model for human hemophilia B.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Functional characteristics of N8, a new recombinant FVIII.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Prolonged activity of factor IX as a monomeric Fc fusion protein

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

A ferric chloride induced arterial injury model used as haemostatic effect model

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952454

The binding of human factor IX to endothelial cells is mediated by residues 3-11

1 September 2018

1 reference

12 December 2020

Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169

1 reference

12 December 2020

Recombinant factor IX

1 reference

12 December 2020

Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols

1 reference

12 December 2020

An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice

1 reference

12 December 2020

Structural analysis of N-linked sugar chains of human blood clotting factor IX

1 reference

12 December 2020

The role of phospholipid and factor VIIIa in the activation of bovine factor X

1 reference

12 December 2020

10.1182/BLOOD-2011-02-336172

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

21700771

1 reference